Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.

"data s1 supporting information click here for additional data file."

"CONFLICT OF INTEREST Carminia Maria Della Corte has served as an advisor for MSD. Morena Fasano has a family relationship with Merck. Evaristo Maiello has served as advisor and speaker for Astra Zeneca, Eli Lilly, Servier, Sanofi Genzyme, Roche, Merck, Eisai and Pfizer. Floriana Morgillo has served as an advisor for MSD, Lilly; Institutional Research Grants: AstraZeneca. Teresa Troiani has served as an advisor and speaker for Roche, Merck‐Serono, Sanofi, Servier, Novartis and Bayer. Erika Martinelli has served as advisor and speaker for Astra Zeneca, Amgen, Bayer, Merck‐Serono, Roche, Sanofi, Servier and Pierre Fabre. Massimo Di Maio has served as an advisor for AstraZeneca, Merck Sharp & Dohme, Pfizer, Novartis, Roche, Takeda Pharmaceuticals, Janssen Pharmaceuticals, Mediolanum Farmaceutici, Eisai, Amgen, Merck Serono and received institutional Research Grant from Tesaro ‐ GlaxoSmithKline. Fortunato Ciardiello has served as advisor and speaker for Roche, Amgen, Merck‐Serono, Pfizer, Sanofi, Bayer, Servier, BMS, Cellgene and Lilly. Received institutional Research Grants from Bayer, Roche, Merck‐Serono, Amgen, AstraZeneca and Takeda. The other authors declare no competing interests."

"Funding Information Two research grants, that partially covered the costs of the study, were provided by Merck and by Regione Campania (I‐Cure Research Project, Grant number: Cup 21C17000030007)"

"CAVE‐mCRC trial was a nonprofit academic, single‐arm phase II study. Patients had histologically confirmed mCRC with RAS (NRAS and KRAS, exon 2, 3 and 4) WT tumors; obtained a complete (CR) or partial response (PR) during first‐line treatment with an anti‐EGFR‐based regimen and, upon progression, received at least one subsequent line of therapy with an interval of more than 4 months from the last dose of the anti‐EGFR drug. Additional inclusion and exclusion criteria are described in the full protocol available online. CAVE‐Lung trial was a nonprofit academic, single‐arm proof‐of‐concept clinical and translational study. Patients were enrolled with histologically confirmed Stage IIIb/IV or recurrent NSCLC and treated as second‐ or third‐line therapy. Additional inclusion and exclusion criteria are described in the full protocol available online. CAVE‐mCRC (clinical trial registration: NCT04561336); CAVE‐LUNG (clinical trial registration: Eudract‐2017‐004195‐58)."